Showing results (21-30 of 143) with videos related to
Sort By:
Pageof 15
Nanomedicine (London, England)|January 20, 2015
Nanobody-based cancer therapy of solid tumorsMarta Kijanka, Bram Dorresteijn, Sabrina Oliveira, et al.Expert Opinion on Biological Therapy|May 19, 2006
Molecular biology of epidermal growth factor receptor inhibition for cancer therapySabrina Oliveira, Paul M P van Bergen en Henegouwen, Gert Storm, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|June 1, 1997
Influence of blockade of alpha 1-adrenoceptors, beta 1-adrenoceptors and vasopressin V1A receptors on the cardiovascular effects of gamma 2-melanocyte-stimulating hormone (gamma 2-MSH)P Van Bergen, T Y De Winter, D J De Wildt, et al.Cancers|September 26, 2020
Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic TherapyVida Mashayekhi, Katerina T Xenaki, Paul M P van Bergen En Henegouwen, et al.Cell Biology International|May 1, 1995
The epidermal growth factorJ Boonstra, P Rijken, B Humbel, et al.Cancer Treatment Reviews|May 16, 2018
MAGE-A antigens as targets for cancer immunotherapyErik Schooten, Alessia Di Maggio, Paul M P van Bergen En Henegouwen, et al.Revue Scientifique Et Technique (International Office of Epizootics)|April 29, 2006
Global detection and identification of Campylobacter fetus subsp. venerealisM A P van Bergen, S Linnane, J P M van Putten, et al.European Journal of Pharmacology|December 29, 1995
Cardiovascular effects of gamma-MSH/ACTH-like peptides: structure-activity relationshipP Van Bergen, P M Janssen, P Hoogerhout, et al.BMC Molecular and Cell Biology|March 2, 2022
Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobodyMatthieu R Zeronian, Sofia Doulkeridou, Paul M P van Bergen En Henegouwen, et al.Current Opinion in Molecular Therapeutics|August 19, 2007
Nanobodies in therapeutic applicationsRob C Roovers, Guus A M S van Dongen, Paul M P van Bergen en HenegouwenPageof 15